Archived Grant Opportunity View - GO1155

The National Blood Sector Research and Development Program forms an important component of the National Blood Authority’s blood sector research and development framework and aims to facilitate world-class research and development in Australia that contributes to optimising the use, management and administration of blood products, and improve patient outcomes. 

The Program is focussed on research areas that have been identified by pre-existing strategic programs of the National Blood Authority and governments in the blood sector. They are:  

• Patient Blood Management  evidence gaps, as identified in the National Blood Authority’s Patient Blood Management Guidelines, and

• efficient and effective use of immunoglobulin products, as highlighted through the Immunoglobulin Governance Program. 

A total of $1.275 million is available under Round 3 of the National Blood Sector Research and Development Program for single year or multiple year projects.  

Grants are offered under three categories as outlined below: 

Project Grants, typically $30,000 to $150,000 per year to be expended over a period of up to three years. Applications should be for an entire, discrete research project proposal. 

Seed Grants, typically under $50,000 to be expended over one year.  Applications for seed funding should be for early stages of innovative new research, or for effort generation of preliminary data needed to support future grant applications. 

Scholarships, typically $25,000 to $30,000 to be expended over one year.  Scholarship grants are intended to support medical researchers in the attainment of a PhD or Master’s degree or postdoctoral research fellow research. 

Application forms are available on the National Blood Authority Website at

  https://www.blood.gov.au/research-and-development

Grant Recipients must be a legal entity and have an Australian Business Number (ABN) or an Australian Company Number (ACN) to receive funding under the program. 

Grant Recipients must be listed on the National Health and Medical Research Council (NHMRC) as an Administering Institution.  This policy is available at:

https://www.nhmrc.gov.au/_files_nhmrc/file/grants/funding/2015/2015_nhmrc_administering_institution_policy_16032015_3.pdf

The list of NHMRC registered Administering Institutions can be found at:

https://www.nhmrc.gov.au/grants-funding-administering-grantsas at 18 December 2017. 

Project and Seed Grants require the Principal Chief Investigator to be an Australian Citizen or a Permanent Australian Resident. 

Scholarship recipients must be an Australian citizen, a permanent resident of Australia, or a New Zealand citizen with Special Category Visa (subclass 444) status.

The National Blood Authority may waive this requirement where it can be demonstrated that the research is based in Australia and will benefit health and medical research in Australia. Additional information about the waiver requirements can be found in the Grant Opportunity Guidelines.

April – May 2018 - Call for applications for Round 3

June - August 2018 - Evaluation of applications

September – November 2018 - Approval of grant funding recommendations, Grant Offers, and commencement of Grant Funding Agreement negotiations.

$1,275,000.00

Applications must be submitted using the specific form relevant to the application and in accordance with the response lodgement procedures set out in the relevant form.  Scholarship applications must also include a completed Scholarship Acknowledgement form.

Applications must be lodged electronically before 5:00pm, Friday 1 June 2018, (Australian Eastern Standard Time).

Applications should be emailed to: 

R&D@blood.gov.aumarked for the attention of the Project Director.

A compliance check will be undertaken by NBA officers on all grant applications to ensure all key information is present. 

The National Blood Authority will undertake a value-for-money assessment of proposals against the appraisal criteria outlined below. The assessment will be undertaken by a panel of expert advisors. The Expert Panel is comprised of members of the Patient Blood Management Steering Committee, Expert Working Group or Clinical Reference Groups (or referred nominees), members of the Immunoglobulin Governance groups (National Immunoglobulin Governance Committee or Specialist Working Groups).

Applications will be assessed on the basis of the following evaluation criteria:

• Research scope, focus and potential value

• Quality

• Governance and ethics

• Efficient and effective use of funds.